Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 3/2018

01-06-2018 | Original Paper

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

Published in: International Ophthalmology | Issue 3/2018

Login to get access

Abstract

Purpose

To provide preliminary data about efficacy and safety of plasma rich in growth factors (PRGF) eye-drops in neurotrophic keratitis (NK) and to analyze the possible influence of certain variables on treatment outcomes.

Methods

This retrospective study included patients with stages 2–3 of NK treated with PRGF eye-drops. Primary endpoint was the resolution time of corneal ulcer defect. Outcome measures including percentage of ulcer closure at 4 weeks, Ocular Surface Disease Index (OSDI), Best-Corrected Visual Acuity (BCVA) and Visual Analogue Scale (VAS) were also evaluated before and after treatment with PRGF. The influence of some patients’ clinical variables on results was assessed. Safety assessment was also performed reporting all adverse events.

Results

Thirty-eight treated eyes in a total of thirty-one patients were evaluated, of which five cases had no prior response to autologous serum treatment. Most cases (97.4%) achieved the complete resolution of corneal defect/ulcer. Mean resolution time was 11.4 weeks (SD = 13.7). A statistical significant (p < 0.05) reduction in OSDI (60.9%), VAS frequency (59.9%), VAS severity (57.0%) and improvement in BCVA (52.8%) was observed. The results were stratified according to the pathology stage and to the identified potential effect modifiers variables. Only one adverse event was reported in one patient (2.6%).

Conclusions

PRGF eye-drops could be a safe and effective therapeutic option for patients with stages 2–3 of NK, showing high rates of corneal defect/ulcer resolution in short times, either in reducing signs and symptoms of NK, and therefore preventing the progression of NK to greater ocular complications.
Literature
1.
2.
3.
Cavanagh HD, Colley AM (1989) The molecular basis of neurotrophic keratitis. Acta Ophthalmol Suppl (Oxf) 192:115–134
4.
Lambiase A, Rama P, Aloe L, Bonini S (1999) Management of neurotrophic keratopathy. Curr Opin Ophthalmol 10(4):270–276CrossRefPubMed
5.
Yoon KC, You IC, Im SK, Jeong TS, Park YG, Choi J (2007) Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology 114(9):1637–1642CrossRefPubMed
6.
Versura P, Buzzi M, Giannaccare G, Terzi A, Fresina M, Velati C, Campos EC (2016) Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops. Blood Transfus 14(2):145–151PubMedPubMedCentral
7.
Versura P, Buzzi M, Giannaccare G, Grillini M, Terzi A, Pagliaro P, Campos EC (2014) Cord blood serum-based eye drops: the impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels. Blood Transfus 12(Suppl 1):44–50
8.
Shen EP, Hu F-R, Lo S-C, Chen Y-M, Sun Y-C, Lin C-T, Chen W-L (2011) Comparison of corneal epitheliotrophic capacity among different human blood-derived preparations. Cornea 30(2):208–214CrossRefPubMed
9.
Jeng BH, Dupps WJ (2009) Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea 28(10):1104–1108CrossRefPubMed
10.
Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, Tsubota K (2004) Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology 111(6):1115–1120CrossRefPubMed
11.
Anitua E, Zalduendo MM, Prado R, Alkhraisat MH, Orive G (2015) Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: evaluation of the effect of leukocyte inclusion. J Biomed Mater Res A 103(3):1011–1020CrossRefPubMed
12.
Anitua E, Zalduendo M, Troya M, Padilla S, Orive G (2015) Leukocyte inclusion within a platelet rich plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties. PLoS ONE 10(3):1–19CrossRef
13.
Anitua E, Sanchez M, Merayo-Lloves J, De la Fuente M, Muruzabal F, Orive G (2011) Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation. Invest Ophthalmol Vis Sci 52(9):6066–6073CrossRefPubMed
14.
Anitua E, Muruzabal F, Alcalde I, Merayo-Lloves J, Orive G (2013) Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery. Exp Eye Res 115:153–161CrossRefPubMed
15.
Anitua E, Muruzabal F, De la Fuente M, Merayo-Lloves J, Orive G (2014) Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res 119:27–34CrossRefPubMed
16.
Anitua E, Muruzabal F, Pino A, Merayo-Lloves J, Orive G (2013) Biological stability of plasma rich in growth factors eye drops after storage of 3 months. Cornea 32(10):1380–1386CrossRefPubMed
17.
Anitua E, Pelacho B, Prado R, Aguirre JJ, Sánchez M, Padilla S, Aranguren XL, Abizanda G, Collantes M, Hernandez M, Perez-Ruiz A, Peñuelas I, Orive G, Prosper F (2015) Infiltration of plasma rich in growth factors enhances in vivo angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia. J Control Release 202:31–39CrossRefPubMed
18.
Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, Desiderio MA (2010) Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kB inhibition via HGF. J Cell Physiol 225(3):757–766CrossRefPubMed
19.
Anitua E, Alonso R, Girbau C, Aguirre JJ, Muruzabal F, Orive G (2012) Antibacterial effect of plasma rich in growth factors (PRGF®-Endoret®) against Staphylococcus aureus and Staphylococcus epidermidis strains. Clin Exp Dermatol 37:652–657CrossRefPubMed
20.
Drago L, Bortolin M, Vassena C, Romanò CL, Taschieri S, Del Fabbro M (2014) Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study. PLoS ONE 9(9):e107813CrossRefPubMedPubMedCentral
21.
Chikama TI, Fukuda K, Morishige N, Nishida T (1998) Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I. Lancet 351(9118):1783–1784CrossRefPubMed
22.
Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L (2000) Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 107:1347–1351CrossRefPubMed
23.
Benowitz LI, Popovich PG (2011) Inflammation and axon regeneration. Curr Opin Neurol 24(6):577–583CrossRefPubMed
24.
25.
26.
Schnabel LV, Mohammed HO, Miller BJ, McDermott WG, Jacobson MS, Santangelo KS, Fortier LA (2007) Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J Orthop Res 25(2):230–240CrossRefPubMed
27.
Yoon K-C, Jeong I-Y, Park Y-G, Yang S-Y (2007) Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea 26(4):431–437CrossRefPubMed
28.
Freire V, Andollo N, Etxebarria J, Durán JA, Morales M-C (2012) In vitro effects of three blood derivatives on human corneal epithelial cells. Invest Ophthalmol Vis Sci 53(9):5571–5578CrossRefPubMed
29.
Anitua E, Prado R, Orive G (2015) Closing regulatory gaps: new ground rules for platelet-rich plasma. Trends Biotechnol 33(9):492–495CrossRefPubMed
30.
Anitua E, Muruzabal F, De la Fuente M, Merayo-Lloves J, Orive G (2014) Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res 119:27–34CrossRefPubMed
31.
Anitua E, de la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G (2015) Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res 135:118–126CrossRefPubMed
32.
Anitua E, Muruzabal F, Tayebba A, Riestra A, Perez VL, Merayo-Lloves J, Orive G (2015) Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol 93:1–10CrossRef
33.
Anitua E, Muruzabal F, de la Fuente M, Merayo J, Duran J, Orive G (2016) Plasma rich in growth factors for the treatment of ocular surface diseases. Curr Eye Res 41(7):875–882CrossRefPubMed
34.
Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, Anitua E, Begona L, Orive G, Fernandez-Vega L (2016) Safety and efficacy of autologous plasma rich in growth factors eye drops for the treatment of evaporative dry eye. Ophthalmic Res 56(2):68–73CrossRefPubMed
35.
Merayo-Lloves J, Sanchez RM, Riestra AC, Anitua E, Begona L, Orive G, Fernandez-Vega L (2015) Autologous plasma rich in growth factors eyedrops in refractory cases of ocular surface disorders. Ophthalmic Res 55(2):53–61CrossRefPubMed
36.
Kim KM, Shin Y-T, Kim HK (2012) Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol 56(6):544–550CrossRefPubMed
37.
Semeraro F, Forbice E, Romano V, Angi M, Romano MR, Filippelli ME, Di Iorio R, Costagliola C (2014) Neurotrophic keratitis. Ophthalmologica 231(4):191–197CrossRefPubMed
38.
Aifa A, Gueudry J, Portmann A, Delcampe A, Muraine M (2012) Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. Invest Ophthalmol Vis Sci 53(13):8181–8185CrossRefPubMed
39.
Brignole-Baudouin F, Warnet JM, Barritault D, Baudouin C (2013) RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies. J Fr Ophtalmol 36(9):740–747CrossRefPubMed
40.
Kymionis GD, Liakopoulos DA, Grentzelos MA, Diakonis VF, Klados NE, Tsoulnaras KI, Tsilimbaris MK, Pallikaris IG (2014) Combined topical application of a regenerative agent with a bandage contact lens for the treatment of persistent epithelial defects. Cornea 33(8):868–872CrossRefPubMed
Metadata
Title
Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops
Publication date
01-06-2018
Published in
International Ophthalmology / Issue 3/2018
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-017-0582-7

Other articles of this Issue 3/2018

International Ophthalmology 3/2018 Go to the issue

Case Report

A case of bilateral keratitis caused by Providencia alcalifaciens: a rarely encountered ocular pathogen

Original Paper

Investigation of corneal biomechanics at moderate to high refractive errors

Original Paper

Etiology and outcomes of secondary surgical intervention for dissatisfied patients after pseudophakic monovision

Case Report

Corneal melting in rheumatoid arthritis patients treated with a tectonic reinforcing corneolimbal graft: an interventional case series

Original Paper

Self-made cryopreservative fibrin glue applied in pterygium surgery: a novel practical technique

Original Paper

A cross-sectional comparative study on chronic ocular manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series